

Enabling earlier and faster cancer diagnosis across the NHS

C the Signs AI Teledermatology Pricing Document

Platform Overview

C the Signs is an AI-driven clinical decision support and cancer case-finding platform designed to identify patients at risk of cancer earlier, standardise referral decision-making, and optimise access to diagnostics across the NHS. Built by NHS clinicians and deployed across the UK since 2017, it integrates directly with Electronic health records to support end-to-end cancer detection within NHS.

C the Signs AI Teledermatology is an AI-enabled skin cancer decision-support and remote assessment service designed to support earlier identification of skin cancer, standardise referral decision-making, and optimise access to dermatology services across the NHS. Built by NHS clinicians, it integrates with electronic health records to support end-to-end skin lesion assessment and referral pathways.

The service enables clinicians to complete structured skin cancer risk assessments using evidence-based logic aligned to NICE guidance and local pathways, supported by AI image analysis. High-quality clinical and dermoscopic images can be captured in primary care, uploaded via skin image clinics, or securely submitted by patients from home. Images are reviewed alongside clinical history to support triage, management advice, or urgent suspected cancer (USC) referral, with standardised referral outputs and pre-referral requirements automatically completed and coded back to the record.

Teledermatology workflows include automated safety-netting to track patients through image submission, review, investigation, diagnosis, or exclusion of cancer, ensuring no patient is lost to follow-up. Dashboards provide real-time visibility of activity, outcomes, and pathway performance at practice, PCN, ICB and Hospital level.

The platform supports multi-care setting image capture, enabling it to be deployed in any care setting but also enabling remote assessment and AI image analysis. The service reduces unnecessary face-to-face appointments, improves prioritisation of high-risk lesions, shortens time to diagnosis, and supports more efficient use of dermatology capacity while improving patient access and experience across skin cancer pathways.

Clinical decision support has been validated in real-world NHS deployments, the platform achieves 99% sensitivity, 94% accuracy, increases cancer detection rates by 8–12%, reduces emergency presentations, and delivers significant stage shift across harder-to-detect cancers.

AI Teledermatology

Teledermatology and image analysis capabilities

Multi setting images are captured: Enables image capture in any clinical setting, primary care, skin imaging hub or submitted directly by the patient

AI image analysis: Analyses submitted images to support assessment accuracy and continuously improve system performance.

AI-powered clinical insight: Supports earlier and more accurate identification of patients at risk of skin cancer, aligned to NICE guidance and local pathways.

Automated safety-netting for every patient: Tracks all images, referrals, and appointments across suspected cancer pathways, ensuring no patient is lost to follow-up.

Surveillance and continuous oversight for diagnosed patients: Provides real-time tracking to support timely review, follow-up, surveillance, and care planning following a cancer diagnosis.

Population-wide risk stratification: Identifies higher-risk patients across populations, enabling proactive assessment and earlier detection.

Real-time cancer performance dashboards: Delivers clear visibility of pathway activity and outcomes across practices, PCNs, ICBs, and hospitals to support improvement and reduce variation.

Multilingual patient communication: Automated SMS and email reminders, guidance, and pathway information to improve engagement and support equitable access to care.

Smart referral forms: Ensures referrals are complete, clinically appropriate, and aligned with local provider requirements, reducing delays and improving safety.

Comprehensive cancer performance data: Accessible across practices, PCNs, ICBs, and Cancer Alliances, enabling continuous quality improvement and earlier diagnosis at scale.

Training and Education Support

C the Signs provides continuous training and education to support implementation and sustain high engagement, includes:

- Attendance at PCN and practice meetings, local cancer events, and secondary care educational sessions
- Dedicated Training webinars
- Workshops to interpret performance metrics and identify areas for improvement.

Technical Support and Maintenance

Helpdesk available 9am–5pm, Monday to Friday (excluding Bank Holidays):

- Remote deployment and maintenance across all practices
- Security and compliance managed in line with NHS Digital and IG requirements
- Continuous updates to align with evolving NICE guidelines and national policies.

Supporting Local Cancer Teams and Pathways

C the Signs collaborates with local cancer teams to:

- Attend alliance and ICB cancer meetings
- Provide routine data reports aligned with local KPIs
- Support pathway redesign and the adoption of new diagnostic services
Facilitate local implementation

Deployment and Governance

Each deployment follows a robust implementation plan, including:

- Information Governance approvals (DPIA & DPA)
- Local configuration of pathways and resources
- Comprehensive communication and engagement plan
- Webinars and live training prior to go-live
- Steering Group oversight with agreed KPIs and data monitoring

Licensing Model

C the Signs AI Telederm is commissioned as an annual licensing model, based on the registered patient population within a defined area. All prices below exclude VAT:

AI Teledermatology

Length of Licence	Per Patient Cost (£)
1 year	0.36p
2 Year	0.32p
3 Year	0.30p

The licence covers all configuration, deployment, and ongoing support, including:

- Configuration of regional cancer pathways and access to services
- Onboarding of all Healthcare organisations
- Training and education support for all clinical & Admin staff throughout the licence period
- Technical support and system maintenance, with a dedicated helpdesk

Customers already using the C the Signs Clinical Decision Support platform can add the AI Telederm at a discounted rate, reflecting reduced deployment and maintenance costs and the use of existing technical infrastructure.

Licence cost when purchasing in addition to Clinical Decision Support:

Length of Licence	Per Patient Cost (£)
1 year	0.16p
2 Year	0.12p
3 Year	0.10p